{"result": "(\"entity\"<|>HIPOONATREMIA<|>EVENT<|>Hiponatremia is a medical condition characterized by low sodium levels in the blood, often requiring treatment with medications like tolvaptán.)\n##\n(\"entity\"<|>FARMACO<|>ORGANIZATION<|>Farmaco refers to medications used in the treatment of various conditions, including tolvaptán and desmopresina for managing sodium levels.)\n##\n(\"entity\"<|>TRANSAMINASAS<|>EVENT<|>Transaminasas are enzymes that can indicate liver function, and their levels are monitored during treatment to avoid complications.)\n##\n(\"entity\"<|>PROTOCOLO<|>EVENT<|>Protocolo refers to the established guidelines for administering tolvaptán and managing sodium levels in patients with SIADH.)\n##\n(\"entity\"<|>ALGORITMO MULTIDISCIPLINAR<|>EVENT<|>El algoritmo multidisciplinar is a comprehensive treatment protocol that outlines the steps for managing patients with SIADH.)\n##\n(\"relationship\"<|>HIPONATREMIA<|>TOLVAPTÁN<|>Tolvaptán is specifically used to treat the condition of hiponatremia by increasing sodium levels in the blood<|>8)\n##\n(\"relationship\"<|>FARMACO<|>TOLVAPTÁN<|>Tolvaptán is a type of farmaco used in the treatment of conditions like SIADH and hiponatremia<|>7)\n##\n(\"relationship\"<|>TRANSAMINASAS<|>TOLVAPTÁN<|>Monitoring transaminasas is important during tolvaptán treatment to prevent liver-related complications<|>6)\n##\n(\"relationship\"<|>PROTOCOLO<|>TOLVAPTÁN<|>The protocolo outlines the administration and dosage of tolvaptán for effective treatment<|>7)\n##\n(\"relationship\"<|>ALGORITMO MULTIDISCIPLINAR<|>PROTOCOLO<|>The algoritmo multidisciplinar serves as a detailed protocol for managing SIADH and related treatments<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , así como en las primeras 24 horas tras\nsu comienzo. Por ello, se recomienda al paciente\nbeber agua si desarrolla sed y compensar así la\nacuaresis inicial, evitando un mayor incremento de\nla natremia en esas primeras 24 horas. Hecho im-\nprobable que suceda, si se inicia el tratamiento si-\nguiendo el protocolo recogido en el algoritmo mul-\ntidisciplinar65 o la adaptación del mismo por alguno\nde los autores81. De tal forma que se administra una\ndosis de 7,5 mg de tolvaptán, con determinación\nde la natremia sérica pre, a las 6 horas y a las 24\nhoras postinicio. Si el incremento de natremia en las\nprimeras 6 horas es superior a 5 mmol/l, para frenar\nla subida de natremia se asocian 3 μg de desmo-\npresina intravenosa o subcutánea y 3 ml/kg/h de\nsuero glucosado al 5% durante 3 horas39, 81.\n\nA las 24 horas del inicio de tolvaptán, si el incremen-\nto de la natremia es menor de 8 mmol/l y la natremia\npersiste inferior a 135 mmol/l administramos 15 mg de\ntolvaptán, siempre y cuando no haya sido necesario\nfrenar la subida con desmopresina. En ese caso, pauta-\nremos 7,5 mg de tolvaptán. Por el contrario, si el incre-\nmento de natremia a las 24 horas ha sido mayor de\n8 mmol/l, aplazamos a un día la siguiente dosis de tol-\nvaptán (7,5 mg). Es importante evitar la administración\nconjunta de otras terapias que incrementen la natre-\nmia (RH y furosemida) y está totalmente contraindica-\ndo su inicio en las primeras 24 horas tras la administra-\nción del suero hipertónico al 3%.\n\nA las 48 horas del comienzo del tolvaptán, se analiza-\nrá de nuevo la natremia y si persiste inferior a 135 mmol/l\nse aumentará la dosis de tolvaptán de 7,5 a 15 mg/día y\nde 15 a 30 mg/día.\n\nSi a las 72 horas no se ha logrado la eunatremia, se\nincrementará de nuevo la dosis de tolvaptán, en 15 mg/\ndía. Aunque la dosis máxima de tolvaptán aprobada\npara el tratamiento de la hiponatremia asociada a\nSIADH es 60 mg/día, raramente se precisan dosis supe-\nriores a 30 mg/día para alcanzar la eunatremia.\n\nUna vez conseguida la eunatremia, se mantiene la\ndosis que la logró. Se recomienda monitorizar la natre-\nmia sérica a la semana y posteriormente de forma\nmensual si la etiología del SIADH persiste. Durante el\nseguimiento, se aconseja disminuir la dosis de tolvap-\ntán en un 50% si la natremia es superior a 140 mmol/l\ny cuando sea necesario reducir la dosis de 7,5 mg/día\naumentar progresivamente el intervalo a 48 horas,\n72 horas y una semana39. Según la experiencia de algu-\nnos autores, los pacientes necesitan progresivamente\nmenos dosis para mantener la eunatremia, salvo en los\ncasos de SIADH ectópico82. Se suspenderá el fármaco\ncuando desaparezca la etiología del SIADH o el pacien-\nte esté durante varias semanas con 7,5 mg/semana.\nTras su retirada se recomienda realizar una natremia a\nlas 2 semanas y reintroducirlo si el descenso de natre-\nmia es superior a 4 mmol/l39. Por otra parte, es impor-\ntante incrementar la dosis del fármaco si el paciente va\na recibir grandes cantidades de líquidos, como en caso\nde la hiperhidratación intravenosa pautada durante la\nquimioterapia. Así como reducir la dosis o espaciar el\nintervalo de administración si el paciente desarrolla al-\ngún episodio de hipovolemia (hemorragias, pérdidas\ngastrointestinales, etc.)39. El principal efecto secunda-\nrio documentado en pacientes con SIADH es un incre-\nmento leve de la sed, sin objetivarse en ningún pacien-\nte un incremento de las transaminasas80, como se ha\ndescrito en algún paciente con poliquistosis renal tra-\ntado con dosis de 120 mg/día. Aun así, no se reco-\nmienda su administración en pacientes con transami-\nnasas elevadas > 3 veces el límite superior de la\nnormalidad (ficha técnica).\n\nAplicación de los tratamientos del SIADH a los\npacientes con nutrición artificial\n\nEn los\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is a medication used to treat hyponatremia associated with SIADH, administered in specific dosages to manage sodium levels in patients.)\n##\n(\"entity\"<|>DESMOPRESINA<|>ORGANIZATION<|>Desmopresina is a medication used to manage sodium levels in conjunction with tolvaptán, particularly when sodium levels rise too quickly.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) is a condition that causes low sodium levels in the blood, requiring careful management of sodium levels through medication.)\n##\n(\"entity\"<|>NATREMIA<|>EVENT<|>Natremia refers to the concentration of sodium in the blood, which is monitored during the treatment of SIADH to ensure proper levels are maintained.)\n##\n(\"entity\"<|>ACUARESIS<|>EVENT<|>Acuaresis is the initial phase of treatment where the body may excrete excess water, affecting sodium levels.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Artificial nutrition refers to the provision of nutrients through methods other than oral intake, which can impact sodium management in patients with SIADH.)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>SIADH<|>Tolvaptán is used to treat the condition of SIADH by managing sodium levels in patients<|>8)\n##\n(\"relationship\"<|>DESMOPRESINA<|>TOLVAPTÁN<|>Desmopresina is used alongside tolvaptán to manage sodium levels when they rise too quickly<|>7)\n##\n(\"relationship\"<|>NATREMIA<|>TOLVAPTÁN<|>Tolvaptán treatment involves monitoring natremia to ensure sodium levels are within the desired range<|>9)\n##\n(\"relationship\"<|>ACUARESIS<|>NATREMIA<|>Acuaresis can affect natremia levels, particularly in the initial treatment phase<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>SIADH<|>Artificial nutrition can influence the management of sodium levels in patients with SIADH<|>5)\n<|COMPLETE|>"}]}